Carbon Biosciences

Carbon Biosciences

Edit info

  • Founded: 2021
  • Location: Lexington, MA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Cystic fibrosis
  • Drug types: LNG, GEN
  • Lead product: CGT-001
  • Funding: $38M A Jun 2022
  • Investors: Agent Capital, Longwood Fund, Solasta Ventures, Astellas, Camford Capital, UTokyoIPC


carbonbio.com

linkedin.com

job board


About:

Carbon Biosciences is using their proprietary CBN vector library to advance gene therapy by increasing tissue specificity and allowing for larger payloads. They are developing genetic medicines utilizing next-generation viral vectors for the treatment of the most devastating and difficult-to-treat diseases. Dr. Robert Kotin, a leader in adeno-associated vector research, and John F. Engelhardt are the scientific founders of Carbon Biosciences in 2021.

Jobs:

Post a job


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com